Inhibitor Therapeutics, Inc.

INTI

US45720M1053

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 19:00:48 04/06/2024 BST			5-day change	1st Jan Change
0.0701 ^USD	-19.98%		-19.98%	-23.80%

05-13	Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-29	Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Commonwealth Biotechnologies, Inc. will Change its Name to HedgePath Pharmaceuticals, Inc

August 19, 2013 at 05:00 am

Effective August 19, 2013, Commonwealth Biotechnologies, Inc. will change its name to HedgePath Pharmaceuticals, Inc.

Latest news about Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Inhibitor Therapeutics, Inc. Announces the Use of Itraconazole to Treat Basal Cell Carcinoma Nevus Syndrome	12-19	CI
Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board	12-19	CI
Inhibitor Therapeutics, Inc. Enters into an Exclusive, Worldwide Licensing Agreement with Johns Hopkins University	12-14	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Inhibitor Therapeutics, Inc. Appoints Michelle Yanez as an Independent Director and a Member of the Audit Committee	18/10/23	CI
Inhibitor Therapeutics, Inc. Appoints Ronald E. Osman as Non-Independent Director on the Board	29/08/23	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Inhibitor Therapeutics, Inc. Announces Board Changes	31/05/23	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Inhibitor Therapeutics, Inc. Announces Retirement of Debra Peattie from the Board of Directors	03/06/22	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/03/22	CI
Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	29/03/22	CI
Inhibitor Therapeutics, Inc. Executes A Letter Agreement with Mayne Pharma to Amend the Loan Agreement and the Facility	18/01/22	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/08/21	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	26/03/21	CI
Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	25/03/21	CI
Inhibitor Therapeutics, Inc. and Mayne Pharma Ventures Pty Ltd Enters Into Loan Agreement	17/12/20	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	16/11/20	CI

Chart Inhibitor Therapeutics, Inc.

Duration

Period

More charts

Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INHIBITOR THERAPEUTICS, INC.	-23.80%	12.08M
VERTEX PHARMACEUTICALS INCORPORATED	+18.46%	125B
REGENERON PHARMACEUTICALS, INC.	+14.74%	108B
BIONTECH SE	-6.11%	23.64B
ARGENX SE	+2.39%	22.39B
GENMAB A/S	-12.11%	17.78B
WUXI APPTEC CO., LTD.	-41.64%	16.43B
BEIGENE, LTD.	-12.91%	16.34B
NEUROCRINE BIOSCIENCES, INC.	+0.74%	13.56B
SAREPTA THERAPEUTICS, INC.	+25.67%	11.59B

Bio Therapeutic Drugs

Inhibitor Therapeutics, Inc.

Equities

INTI

US45720M1053

Biotechnology & Medical Research

Commonwealth Biotechnologies, Inc. will Change its Name to HedgePath Pharmaceuticals, Inc

Latest news about Inhibitor Therapeutics, Inc.

Chart Inhibitor Therapeutics, Inc.

Company Profile

Income Statement Evolution

Sector Bio Therapeutic Drugs